Citius Pharmaceuticals' subsidiary, Citius Oncology, announced strong commercial momentum for its cancer treatment LYMPHIR®, which is used for cutaneous T-cell lymphoma (CTCL). The company highlighted significant quarter-over-quarter growth in new institutional accounts and vial orders, indicating successful market adoption since its launch.
Key Details
- Account Growth: The number of new institutions ordering LYMPHIR increased by 78% for the quarter ended June 30, 2026, compared to the prior quarter.
- Sales Volume: Vial orders from institutions rose 31% during the same period, with the treatment now available in 42 institutions, including major cancer centers.
- Market & Outlook: The initial CTCL market for LYMPHIR is estimated to exceed $400 million. The company aims for formulary inclusion at 100 priority institutions by the end of 2026.